ARK Invest Allocates $10M to CRISPR Therapeutics and PayPay in Latest Trading Session

TLDR

• ARK Invest acquired 112,815 shares of CRISPR Therapeutics worth approximately $5.63M via ARKK and ARKG ETFs
• The firm secured 275,000 shares of PayPay Corp valued at roughly $4.4M through its ARKF fintech ETF
• Additional purchases included GeneDx (approximately $4.43M) and Tempus AI (around $991K)
• ARK divested from Teradyne (roughly $3.3M) and Ionis Pharmaceuticals (about $3.26M)
• The firm also decreased holdings in 10x Genomics and Circle Internet Group

Cathie Wood’s ARK Invest executed more than $10 million worth of stock purchases on March 12, 2026, while simultaneously reducing exposure to multiple portfolio holdings, based on the company’s publicly disclosed trading activity.

The day’s most substantial acquisition involved CRISPR Therapeutics. ARK accumulated 112,815 shares distributed across two exchange-traded funds — the ARK Innovation ETF and the ARK Genomic Revolution ETF — totaling approximately $5.63 million in value.

CRISPR Therapeutics AG, CRSP

CRISPR Therapeutics specializes in gene-editing biotechnology. This acquisition demonstrates ARK’s ongoing conviction in genomic medicine’s future prospects.

The second-largest purchase targeted PayPay Corp, a company operating in the digital payments sector. ARK secured 275,000 shares via its ARK Fintech Innovation ETF, representing an investment of approximately $4.4 million.

PayPay Corp experienced a 13.50% price surge during the trading session. This investment reinforces ARK’s strategic emphasis on fintech infrastructure and digital payment solutions.

ARK expanded positions in two additional companies as well. The firm acquired 52,075 shares of GeneDx, which operates in genomic diagnostics, valued at approximately $4.43 million. Additionally, it purchased 18,820 shares of Tempus AI, an artificial intelligence-driven healthcare data platform, for around $991,000.

Where ARK Pulled Back

Regarding divestments, ARK offloaded 10,919 shares of Teradyne, which manufactures semiconductor testing equipment, through the ARK Innovation ETF for approximately $3.3 million. Teradyne’s stock declined 5.09% during the session.

This divestment represents a continuation of recent activity. ARK has been systematically reducing its Teradyne exposure across multiple trading days.

ARK additionally disposed of 43,533 shares of Ionis Pharmaceuticals via its ARKG ETF, valued at about $3.26 million. Ionis stock decreased 3.28% on the day.

The Ionis divestment aligns with a broader pattern of ARK reducing its stake in the RNA-focused pharmaceutical developer.

ARK scaled back two additional positions as well. It divested 18,392 shares of 10x Genomics, which develops gene expression technology platforms, for approximately $376,000 across both ARKK and ARKG funds.

The firm also sold 11,194 shares of Circle Internet Group, a blockchain payments and stablecoin company, through ARKK for roughly $1.26 million.

What Analysts Say

Analyst consensus currently assigns “Strong Buy” ratings to both GeneDx and Ionis Pharmaceuticals. GeneDx exhibits the strongest projected upside potential among these holdings, approaching approximately 100%.

CRISPR Therapeutics, Tempus AI, Teradyne, and 10x Genomics each receive “Moderate Buy” ratings from Wall Street analysts. PayPay Corp holds a “Hold” rating.

ARK executed an additional smaller acquisition of 54,736 shares in Canton Strategic Holdings via its ARKF ETF, worth approximately $254,522.

The post ARK Invest Allocates $10M to CRISPR Therapeutics and PayPay in Latest Trading Session appeared first on Blockonomi.